<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430559</url>
  </required_header>
  <id_info>
    <org_study_id>A9001449</org_study_id>
    <nct_id>NCT01430559</nct_id>
  </id_info>
  <brief_title>Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Multicentre Parallel Group Study Of The Effect Of Meloxicam In Mainland Chinese Patients With Osteoarthritis Of The Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index
      (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will
      also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis
      in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To validate culturally the WOMAC tool in mainland China and observe the different response of
      meloxicam and placebo in a patient population with osteoarthritis of the knee
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC and the three subscales (pain, stiffness and physical function) at two screenings, baseline and Week 12 to allow the above mentioned validity/reliability/sensitivity analysis</measure>
    <time_frame>Weekly for 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in WOMAC pain subscale scores at Week 12 from baseline between meloxicam and placebo</measure>
    <time_frame>At week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All WOMAC subscales (ie, pain, physical function and stiffness), change from baseline to Weeks 2, 4, 8, and 12 between meloxicam and placebo;</measure>
    <time_frame>Baselineto week 12 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC pain subscale items, change from baseline to Weeks 2, 4, 8, and 12;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC average change from baseline to Weeks 2, 4, 8, and 12 between meloxicam and placebo;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative distribution of percent change from baseline in the WOMAC pain subscale score to Weeks 2, 4, 8, and 12 between meloxicam and placebo;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response: reduction in the WOMAC pain subscale of greater than or equal to 30% and greater than or equal to 50% at Weeks 2, 4, 8, and 12 between meloxicam and placebo;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of OA (PGAO) (5-point Likert scale) change from baseline to Weeks 2, 4, 8, and 12 between meloxicam and placebo;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response: improvement of greater than or equal to 2 points in PGAO at Weeks 2, 4, 8, and 12;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Survey (Appendix 4) change from baseline to Week 12 between meloxicam and placebo;</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D change from baseline to Week 12 between meloxicam and placebo;</measure>
    <time_frame>baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain score (daily diary) in the index knee change from baseline to Weeks 2, 4, 8, and 12 between meloxicam and placebo by using the 11 point Numeric pain rating scale</measure>
    <time_frame>baseline to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Placebo capsules once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>7.5mg x2 once a day for 12 weeks</description>
    <arm_group_label>Meloxicam</arm_group_label>
    <other_name>Mobic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects are required to meet the following criteria to be eligible for Randomization into
        this study:

          -  Male or female Chinese subjects, 18-75 years of age;

          -  Subjects must have a diagnosis of OA of the index knee based on American College of
             Rheumatology criteria with X ray confirmation (a Kellgren Lawrence x ray grade of
             greater than or equal to 2) (Kellgren J. &amp; Lawrence J, 1957)

          -  Subjects must have have an NRS and a WOMAC pain sub scale score of 4 at Screening and
             at Baseline based on four daily diary entries

        Exclusion Criteria:

        Subjects presenting with any of the following will not be included in the study:

          -  History of other disease that may involve the index (painful) knee including
             inflammatory joint diseases or have had recent surgical intervention on the knee.

          -  Diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or
             duodenal ulceration within 30 days prior to receiving the first dose of study
             medication. History of or active gastrointestinal disease (eg, inflammatory bowel
             disease), a chronic or acute renal or hepatic disorder, or a significant coagulation
             defect.

          -  Signs and symptoms of clinically significant cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shantou City</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>252000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9001449&amp;StudyName=Effect%20Of%20Meloxicam%20Versus%20Placebo%20In%20Mainland%20Chinese%20Patients%20With%20Osteoarthritis%20Of%20The%20Knee%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Validation of the WOMAC in Chinese subjects with osteoarthritis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

